15 March 2024
EMA/CVMP/117304/2024
Committee for Veterinary Medicinal Products (CVMP)

CVMP list of questions to be addressed in an oral explanation by the MAH for

Kexxtone 32.4 g continuous-release intraruminal device for cattle (EU/2/12/145/001-003)

Procedure under Article 130(4) of Regulation (EU) 2019/6

Procedure number: EMEA/V/A/150

INN/active substance: monensin

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

With regard to the above-mentioned procedure, the MAH for Kexxtone is requested to address the following **in an oral explanation**:

1. The Corrective and Preventive Actions (CAPAs) proposed during the quality defect procedure

   [redacted]

   only relate to in-process controls and no changes are proposed to finished product release specification. It is therefore unclear how the MAH will demonstrate that the proposed CAPAs will be effective in-vivo.

   [redacted]

   The MAH is requested to investigate including an additional CAPA, to develop a method that can distinguish between batches of acceptable and unacceptable quality with respect to tablet payout in-vivo and adding this new test to the release specification. In the event that a suitable test is developed the appropriate variation should be submitted. If it is not possible to develop such a test, the MAH should discuss how they will demonstrate the effectiveness of the CAPAs.

2. Within the 8th PSUR, the CVMP discussed the MAH's proposal for an improvement to the intraruminal device in order to decrease the broken wings, and therefore, reduce the incidence of regurgitation, by replacing the material [redacted] for a higher strain-to-break material [redacted]. The MAH was requested to review the status of this possible improvement after application of this measure and to provide an update and a timetable of when it would be submitted to EMA. The MAH concluded that the change in the resin did not require a variation as the starting materials and finished product continued to meet all registered specifications. However, the MAH committed to assess the impact of this change by continuing to monitor reports of regurgitation of the bolus as part of ongoing monitoring of the safety profile of the veterinary medicinal product (VMP) in conjunction with routine signal detection processes. Apart from that, and given that regurgitated boluses with incomplete payout have been reported, the MAH is requested to provide an update on this matter.

3. In light of the currently available data including the MAH's written responses within the quality defect procedure confirming that regurgitation of boluses with incomplete payout continues to be reported and affects batches other than those previously identified (focus period), the MAH is requested to provide an evaluation of the benefit-risk balance of this VMP, with particular attention

to potential lack of efficacy in the target species and serious adverse events in non-target species (dogs).

It should be noted that in addition to the questions raised in this document, the CVMP may consider other available data related to the quality, safety and efficacy of the VMP concerned.